The revelation this week by film star Angelina Jolie of a double mastectomy to help avoid breast cancer had business and legal angles as well.
Myriad Genetics, the Utah company at the center of a legal debate about the acceptability of gene patenting, has a monopoly on the testing Jolie underwent before opting for surgery.
After Jolie’s disclosure, the stock rose to a three-year high before falling back somewhat later in the week.
Jolie explained her decision in an op-ed piece in the New York Times.
“The cost of testing for BRCA1 and BRCA2, at more than $3,000 in the United States, remains an obstacle for many women,” Jolie wrote, referring to the genes. A mutation of the genes can indicate a greater chance of cancer.
Myriad spokesman Ron Rogers said this week that while the company wished Jolie well and was pleased that she encouraged other women with a family history of breast and ovarian cancer to get tested, the company disagreed with her on the cost being an obstacle. Rogers said insurance covers 95 percent of patients with a copayment of about $100. For those without insurance, the company offers discounts and provided 5,000 free tests in the past three years. The Affordable Care Act will require insurers to cover such tests.
“Everyone who is at risk should absolutely go get the BRCA test,” Julie Kessel, senior medical director overseeing the coverage policy unit at insurer Cigna, was quoted as saying in a story on MarketWatch.com.
Women who could not afford the test in previous years were among the original plaintiffs in a lawsuit that is pending before the U.S. Supreme Court. The basic issue is whether Myriad — or any company or person — should be allowed a patent on a human gene. The court heard oral arguments April 15 and is likely to issue a decision before the end of the current term in June.
Myriad is heavily dependent on the revenue from testing for these genes.
“Revenue from the BRACAnalysis test, which represented 74 percent of total revenue in the third quarter, was $115.4 million, a 9 percent increase over the same period of the prior year,” Myriad said in a press release that accompanied its recent quarterly earnings report.
This week’s Supreme Court decision on seed patents in favor of Monsanto in Bowman v. Monsanto et al. might have also been a factor. MarketWatch.com reported that William Blair analyst Amanda Murphy said in an email that the court recognized the investment that companies like Monsanto have to make in research and development, and that issue was also discussed during oral arguments in the Myriad case.